Panel recommends at least 7 hours of sleep a night for most adults
the ONA take:
According to new recommendations from a panel led by a University of Washington sleep expert, adults needs at least 7 hours of sleep each night for best health.
The panel analyzed data from 5,300 scientific articles to determine the optimal amount of sleep each night for best health. The researchers found that people should be getting 7 hours of sleep, but 9 or more hours each night may be best for young adults, ill patients, and people recovering from sleep deficits.
Sleeping less than 7 hours each night is associated with depression, diabetes, heart disease, hypertension, and weight gain and obesity, as well as an increased risk for early death. Not enough sleep is also associated with decreased work performance, increased risk of accidents and errors, greater pain sensitivity, and reduced immune system function.
"Seven hours - that's the lower limit of the threshold," said Dr. Nathaniel F. Watson, a professor of neurology and co-director of the UW Medicine Sleep Center. "We don't want people walking away thinking, 'I need only seven hours of sleep a night.'"
Adults needs at least 7 hours of sleep each night for best health.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|